ArticleHaematologica2017

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Jorge Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.